LAS VEGAS, NV –
innovative, all-natural dietary supplements, announces the achievement of
multiple Equine Championship Titles attributed to the advanced proprietary supplements
sold by its subsidiary, Livestock Impact, Inc.
The highlight of the 2023 season was the spectacular performance of Cheyanne
Colclasure with her 23 year old horse, Docs
Dual Quixote, who secured the 35,000 Non Pro National Championship Title at the
2023 United States Cutting Horse Association (USCHA) National Championship
annual competition in November. Notably, in 2023, Docs Dual Quixote, and
multiple other horses maintained on Livestock Impact supplements have become
National Champions, Reserve Champions and Top 5 members of various competitive classes.
Livestock Impact All-In-One supplement formulas for animals have
been developed during the last five years to generally foster overall health and to specifically increase, speed, performance, resiliency, and endurance
in equine. According to many observers,
horses and dogs maintained on the All-In-One products display certain rejuvenating
effects such as improved energy, agility, responsiveness. and reaction time.
Denise Colclasure, exclusive distributor for Livestock
Impact, Inc., comments, “ We routinely see older horses, like Docs Dual Quixote
(23), that are well beyond the average competition retirement age, standing in
the Winner’s Circle because they are maintained on the popular Livestock Impact
All-In-One products. To my knowledge,
there are no other supplement formulas for animals with these rejuvenating
About BioAdaptives, Inc.
BioAdaptives, Inc. manufactures and distributes natural plant- and
algal-based products that improve health and wellness for humans and animals,
with an emphasis on optimizing pain relief, antiviral activity and immune
system defense; resistance to stress; endurance; recovery from injury, illness
and exercise; and anti-aging properties. The Company’s current dietary
supplement formulations are carefully selected from the best worldwide sources
and utilize proprietary methods of enhancing the bioavailability of nutrients.
The products for horses and dogs have also demonstrated increased general
health, competitive performance enhancement, rejuvenation effects, and pain
relief, as well as providing improvements in appearance. Our current product
line includes PrimiLungs™ and PluriPain® for humans and Equine All-in-One™ for
horses. Additional human products, to be introduced soon, are designed to aid
memory, cognition and focus; assist in sleep and fatigue reduction; and improve
overall emotional and physical wellness. BioAdaptives’ common shares trade in
the OTC market under the symbol BDPT. It has over 13,000 current shareholders.
None of the statements about the Company’s products have been approved by the
Food and Drug Administration. These products are not intended to diagnose,
treat, cure or prevent any disease.
Additional information can be found at www.shopbioadaptives.com or in
our SEC filings at
Safe Harbor Statement
This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All statements, trends,
analysis, and other information contained in this press release including words
such as “anticipate,” “believe,” “plan,”
“estimate,” “expect,” “intend,” and other similar
expressions of opinion, constitute forward-looking statements. Any such
forward-looking statements involve risks and uncertainties that could cause
actual results to differ materially from any future results described within
the forward-looking statements. Risk factors that could contribute to such
differences include those matters more fully disclosed in the Company’s reports
filed with the Securities and Exchange Commission. The forward-looking
information provided herein represents the Company’s estimates as of the date
of the press release, and subsequent events and developments may cause the
Company’s estimates to change. The Company specifically disclaims any
obligation to update the forward-looking information in the future. Therefore,
this forward-looking information should not be relied upon as representing the
Company’s estimates of its future financial performance as of any date
subsequent to the date of this press release.